Goldline Pharmaceutical first-half PAT rises to Rs 2.05 crore

Goldline Pharmaceutical Limited reported profit after tax of Rs 2.05 crore for the half year ended September 30, 2026, up from Rs 1.42 crore a year earlier, while revenue from operations increased to Rs 14.93 crore from Rs 13.89 crore. The unaudited standalone results were approved by the board on November 14, 2026.

How did Goldline Pharmaceutical perform in the September 2026 half year?

Goldline Pharmaceutical increased profit after tax by Rs 63.19 lakh year on year to Rs 2.05 crore in the half year ended September 30, 2026. Profit before tax rose to Rs 2.32 crore from Rs 1.85 crore in the half year ended September 30, 2025, while total expenses increased to Rs 12.61 crore from Rs 12.04 crore.

Revenue from operations rose by Rs 1.03 crore to Rs 14.93 crore from Rs 13.89 crore in the comparable prior-year half. Total income was also Rs 14.93 crore in the latest period because the statement did not record other income, whereas total income in the March 2026 half year included Rs 0.11 lakh of other income.

Goldline Pharmaceutical reported basic and diluted earnings per equity share of Rs 2.31 for the September 2026 half year, compared with Rs 1.96 a year earlier. The filing presents standalone financial results and says the company operates in the marketing and distribution of pharmaceutical products.

Why did Goldline Pharmaceutical revenue decline from the preceding half year?

Goldline Pharmaceutical revenue declined by Rs 2.38 crore from the preceding half year, falling to Rs 14.93 crore in the September 2026 half year from Rs 17.31 crore in the half year ended March 31, 2026. Despite that sequential decline, revenue was Rs 1.03 crore above the Rs 13.89 crore reported in the September 2025 half year.

The filing does not provide a management explanation for the movement between the March and September 2026 half years. It states that Goldline Pharmaceutical has one business, marketing and distribution of pharmaceutical products, and consequently does not provide segment information under Accounting Standard 17 on segment reporting.

Profit after tax also decreased sequentially by Rs 71 lakh from Rs 2.76 crore in the March 2026 half year. Profit before tax fell by Rs 1.22 crore from Rs 3.53 crore, while total expenses declined by Rs 1.16 crore from Rs 13.77 crore over the same two periods.

The reported comparison shows that costs were lower in the September 2026 half year, but revenue and profit were also below the immediately preceding half year. The results do not separately disclose changes in sales volumes, pricing, product mix or customer additions that could explain those movements.

What changed in Goldline Pharmaceutical balance sheet?

Goldline Pharmaceutical total assets rose to Rs 33.31 crore at September 30, 2026 from Rs 28.87 crore at March 31, 2026. Shareholders’ funds increased to Rs 25.94 crore from Rs 14.25 crore, comprising share capital of Rs 11.41 crore and reserves and surplus of Rs 14.53 crore.

Trade receivables increased to Rs 18.53 crore at September 30, 2026 from Rs 16.13 crore at the March 2026 year-end. Inventories declined to Rs 5.98 crore from Rs 6.21 crore, while cash and cash equivalents rose to Rs 1.56 crore from Rs 0.59 crore.

Long-term borrowings decreased to Rs 66.65 lakh at September 30, 2026 from Rs 1.46 crore at March 31, 2026. Current liabilities fell to Rs 5.58 crore from Rs 12.11 crore, and the September 2026 balance sheet shows no amount for short-term borrowings compared with Rs 6.60 crore at the prior year-end.

Short-term loans and advances were Rs 2.43 crore at September 30, 2026, compared with Rs 1.98 crore at March 31, 2026. Other current assets increased to Rs 1.74 crore from Rs 1.13 crore, while the filing does not identify the underlying reasons for these balance-sheet changes.

What does Goldline Pharmaceutical cash flow show?

Goldline Pharmaceutical generated Rs 10.93 lakh of cash from operating activities for the period ended September 30, 2026, after reporting Rs 2.32 crore of profit before extraordinary items and tax. Operating cash flow before working-capital changes was Rs 2.71 crore, while working-capital changes were an outflow of Rs 2.59 crore.

Trade receivables accounted for a Rs 2.40 crore outflow in the cash-flow statement, and other current assets used Rs 60.54 lakh. Short-term loans and advances used Rs 44.38 lakh, while inventories contributed Rs 22.79 lakh to the reported working-capital movement.

Net cash used in investing activities was Rs 66,000 for the period ended September 30, 2026. Financing activities generated Rs 86.01 lakh, with the statement recording Rs 2.70 crore of proceeds from share capital, Rs 7.70 crore of net repayment of short-term borrowings and Rs 79.66 lakh of net repayment of long-term borrowings.

Goldline Pharmaceutical reported a net increase of Rs 96.28 lakh in cash and cash equivalents, ending the period with Rs 1.56 crore. The financing section also records finance cost of Rs 27.92 lakh and share issue expenses of Rs 1.76 crore.

Were Goldline Pharmaceutical September 2026 results reviewed by the auditor?

Goldline Pharmaceutical September 30, 2026 standalone results were unaudited and subject to a limited review by B Shroff & Co. The auditor’s report dated November 14, 2026 said nothing had come to its attention to indicate that the results were not prepared in accordance with applicable accounting standards and disclosure requirements.

The Audit Committee reviewed and recommended the results on November 14, 2026, and the board approved them on the same date. Goldline Pharmaceutical separately declared that the limited review report was unmodified and without qualification, while the auditor noted that a review is narrower in scope than an audit.

The results were prepared under Accounting Standards prescribed under Section 133 of the Companies Act, 2013, according to the notes. Goldline Pharmaceutical also said prior-period figures had been regrouped, rearranged, reclassified or restated where necessary to improve comparability.

Conclusion

Goldline Pharmaceutical delivered higher year-on-year revenue, profit before tax and profit after tax in the half year ended September 30, 2026. The sequential comparison was different: revenue and profit after tax were lower than in the March 2026 half year, while trade receivables rose by Rs 2.40 crore from the March 2026 balance-sheet date.

The next disclosed matter to watch is the Code on Social Security, 2020. Goldline Pharmaceutical said the implementation date and related rules remain unnotified, and that it will assess and recognise any effect on employee-benefit contributions, including provident fund and gratuity, once they are notified.